original ) (raw )Knowledge and Attitudes of Saudi Emergency Physicians toward t-PA Use in Stroke
Haifa Issa
Neurology Research International
View PDFchevron_right
Emergency Nurses' Knowledge and Practice Regarding Care of Acute Ischemic Stroke PatientsUndergoing Recombinant Tissue Plasminogen Activator
IOSR Journals
View PDFchevron_right
Barriers to Receiving Tissue Plasminogen Activator in Patients with Ischemic Stroke
Moniralsadat Mirzadeh , Journal of Inflammatory Diseases (J Inflamm Dis)
View PDFchevron_right
Agreement with evidence for tissue Plasminogen Activator use among emergency physicians: a cross-sectional survey
Christine Paul
BMC research notes, 2015
View PDFchevron_right
Effect of Public Education Regarding Stroke Warning Signs on Pre-Hospital Delay and Frequency of Tissue Plasminogen Activator Therapy in Stroke Patients
Tabandeh Sadeghi
Jundishapur Journal of Chronic Disease Care
View PDFchevron_right
Treatment of acute ischemic stroke with recombinant tissue plasminogen activator: practice pattern among neurologists and physicians
Yaseen Mohammed
International Journal of Basic & Clinical Pharmacology, 2016
View PDFchevron_right
Effect of Public Education Regarding Stroke Warning Signs on Pre-Hospital Delay and Frequency of Tissue Plasminogen Activator Therapy in Stroke Patients: A Quasi-Experimental Study
Amir Moghadam-Ahmadi
Jundishapur Journal of Chronic Disease Care, 2020
View PDFchevron_right
Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients
Homayoun Sadeghi
Iranian Journal of Neurology, 2018
View PDFchevron_right
Enablers of the Implementation of Tissue Plasminogen Activator in Acute Stroke Care: A Cross-Sectional Survey
Alice Grady
PLoS ONE, 2014
View PDFchevron_right
The Outcome of Treatment With Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke
Caspian Journal of Neurological Sciences (CJNS)
View PDFchevron_right
Obstacles to the use of intravenous tissue plasminogen activator for acute ischemic stroke. Is time the only barrier?
Vincent Thijs
Acta neurologica Belgica, 2007
View PDFchevron_right
Physician knowledge of the benefits, risks, and contraindications of tissue plasminogen activator for acute ischemic stroke
Arturo Tamayo
Stroke; a journal of cerebral circulation, 2001
View PDFchevron_right
Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department
devorah nazarian
Annals of emergency medicine, 2015
View PDFchevron_right
Observational Study of Telephone Consults by Stroke Experts Supporting Community Tissue Plasminogen Activator Delivery
William Meurer
Academic Emergency Medicine, 2012
View PDFchevron_right
Stroke at Academic Medical Centers Re: Utilization of Intravenous Tissue-Type Plasminogen Activator for Ischemic
Deborah Barnbaum
2010
View PDFchevron_right
Re: utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers
Deborah Barnbaum
Stroke; a journal of cerebral circulation, 2001
View PDFchevron_right
Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Population-Based Study
Edward Jauch
Stroke, 2004
View PDFchevron_right
Poor Outcomes in Patients Who Do Not Receive Intravenous Tissue Plasminogen Activator Because of Mild or Improving Ischemic Stroke
Abdul Abdullah
2010
View PDFchevron_right
Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke
Maxim Hammer
Archives of Neurology, 2004
View PDFchevron_right
Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator: A Science Advisory From the American Heart Association/American Stroke Association
Jeffrey L Saver , Edward Jauch
Stroke, 2009
View PDFchevron_right
The Early Outcomes of Nurse Case Management in Patients with Acute Ischemic Stroke Treated with Intravenous Recombinant Tissue Plasminogen Activator: A Prospective Randomized Controlled Trial
urai kummarg
Neurology Research International
View PDFchevron_right
Intravenous recombinant tissue plasminogen activator for acute stroke in Poland: an analysis based on the Safe Implementation of Thrombolysis in Stroke (SITS) Registry
Anna Czlonkowska
Acta Neurologica Scandinavica, 2009
View PDFchevron_right
Utilization and outcomes with low dose tissue plasminogen activator as intravenous thrombolytic therapy for ischemic stroke at Aga Khan University Hospital, Karachi: a retrospective analysis
Ammar Khan
Journal of the Pakistan Medical Association, 2019
View PDFchevron_right
Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: A metaanalysis
Nawal Ait Ahmed
2011
View PDFchevron_right
Investigating the Effect and Immunity of Tissue Plasminogen Activator in the Treatment of Acute Ischemic Stroke
Lifescience Global Canada
Journal of Intellectual Disability - Diagnosis and Treatment, 2020
View PDFchevron_right
Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial
Charles Moomaw
Stroke; a journal of cerebral circulation, 2012
View PDFchevron_right
Low-Dose Tissue Plasminogen Activator and Standard-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke in Asian Populations: A Review
SIVA RAMAIAH B V
Cerebrovascular Diseases, 2013
View PDFchevron_right
Gaps and Hurdles Deter against Following Stroke Guidelines for Thrombolytic Therapy in Iran: Exploring the Problem
Abolfazl Avan
Journal of stroke and cerebrovascular diseases, 2015
View PDFchevron_right